No Prescription |
 |
 | ||
|
Casodex Generic Bicalutamide |
|
| ||
No Prescription » Prescription Drugs 3 » Casodex Generic Bicalutamide Product Origin: EU (Turkey) This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English. Medical Information: Bicalutamide is an antiandrogen. It works in the body by preventing the actions of androgens (male hormones). Bicalutamide is used in the treatment of prostate cancer. Nonsteroidal antiandrogens are used to treat cancer of the prostate gland. The prostate gland is present only in males; therefore females do not get prostate cancer. CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic carcinoma of the prostate. Buy Casodex Generic Bicalutamide and other Prescription Drugs 3 products online at Medstore. 3645
About Casodex Generic Bicalutamide: Product Type: Prescription Drugs 3 Casodex ( Generic Bicalutamide ) Casodex (Generic Bicalutamide) Generic Bicalutamide 50mg 28 Tablets Generic Bicalutamide Casodex
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
